The study aims to compare the efficacy, safety and pharmacokinetics (PK) of an optimised
dosing to a standard dosing regimen of vancomycin in neonates and infants aged ≤ 90 days with
late onset bacterial sepsis known or suspected to be caused by Gram-positive microorganisms
Phase:
Phase 2
Details
Lead Sponsor:
PENTA Foundation
Collaborators:
Aristotle University Of Thessaloniki Bambino Gesù Hospital and Research Institute Cardiff University Consorzio per Valutazioni Biologiche e Farmacologiche European Commission Institut National de la Santé Et de la Recherche Médicale, France Robert Debré Hospital Servicio Madrileño de Salud, Madrid, Spain St George's, University of London SYNAPSE Research Management Partners S.L Therakind limited University of Edinburgh University of Liverpool University of Tartu